Literature DB >> 2060530

Models for evaluating compounds for activity against Pneumocystis carinii.

M S Bartlett1.   

Abstract

Cultures and animal models have been developed to provide reproducible and uniform systems for evaluation of compounds for effects on Pneumocystis carinii. The culture model allows rapid low-cost screening of drugs for activity against trophozoite forms. The animal models allow testing of efficacy for prophylaxis and therapy of Pneumocystis carinii pneumonia.

Entities:  

Mesh：

Year:  1991        PMID： 2060530     DOI： 10.1007/bf01964463

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  6 in total

1.  Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection.

Authors:  S F Queener; M S Bartlett; M A Jay; M M Durkin; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo.

Authors:  S F Queener; M S Bartlett; J D Richardson; M M Durkin; M A Jay; J W Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

3.  Cultivation of Pneumocystis carinii with WI-38 cells.

Authors:  M S Bartlett; P A Verbanac; J W Smith
Journal:  J Clin Microbiol       Date:  1979-12       Impact factor: 5.948

4.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

5.  Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats.

Authors:  J W Smith; M S Bartlett; S F Queener; M M Durkin; M A Jay; M T Hull; R S Klein; J J Marr
Journal:  Diagn Microbiol Infect Dis       Date:  1987-06       Impact factor: 2.803

6.  Improved rat model for studying Pneumocystis carinii pneumonia.

Authors:  M S Bartlett; S F Queener; M A Jay; M M Durkin; J W Smith
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948
  6 in total
  1 in total

1.  In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.

Authors:  P Aviles; E M Aliouat; A Martinez; E Dei-Cas; E Herreros; L Dujardin; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.